Clinical trial
CT-2106 for the Second Line Treatment of Ovarian Cancer
NCT00291837 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00291837 |
|---|---|
| Title | CT-2106 for the Second Line Treatment of Ovarian Cancer |
| Official title | Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | CT-2106 |
| Enrollment | 40 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Feb 15, 2006 |
| Last update posted | Feb 26, 2010 |
| Countries | France, Italy, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: